Global Peritoneal Cancer Pipeline Research Report 2021: Focus on 50+ Companies and 50+ Pipeline Drugs -

DUBLIN--()--The "Peritoneal Cancer - Pipeline Insight, 2021" clinical trials has been added to's offering.

"Peritoneal cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 50+ companies and 50+ pipeline drugs in Peritoneal cancer pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal cancer.

Peritoneal cancer Emerging Drugs Chapters

This segment of the Peritoneal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritoneal cancer Emerging Drugs

Mirvetuximab soravtansine: ImmunoGen

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FR?)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The drug is being studied in phase III stage of development for the treatment of patients with peritoneal cancer.

Pembrolizumab: Merck & Co

Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. Currently it is being evaluated in Phase III stage of development for the treatment of peritoneal cancer.


SOTIO's DCVAC Program is a cell therapy platform designed to improve efficacy compared to earlier generations of dendritic cell therapies by targeting multiple antigens and applying an immune-stimulatory technique. SOTIO has created this vertically integrated, personalized cell therapy platform to enable the efficient manufacturing of product doses for one year of treatment at commercially attractive costs. It is currently being evaluated in Phase III clinical trial to treat peritoneal cancer.

PF-06873600: Pfizer

PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. The drug is being investigated in Phase II stage of development for the treatment of peritoneal cancer, HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, and Fallopian Tube Cancer.

Major Players in Peritoneal cancer

There are approx. 50+ key companies which are developing the therapies for Peritoneal cancer. The companies which have their Peritoneal cancer drug candidates in the most advanced stage, i.e. Phase III include, ImmunoGen.

Key Questions Answered

  • How many companies are developing Peritoneal cancer drugs?
  • How many Peritoneal cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peritoneal cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peritoneal cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Topics Covered:


Executive Summary

Peritoneal cancer: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Mirvetuximab soravtansine: ImmunoGen

  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

PF-06873600: Pfizer

  • Product Description
  • Research and Development
  • Product Development Activities

Early stage products (Phase I/II)

  • Comparative Analysis

ART0380: Artios Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products

  • Comparative Analysis

Peritoneal cancer Key Companies

Peritoneal cancer Key Products

Peritoneal cancer- Unmet Needs

Peritoneal cancer- Market Drivers and Barriers

Peritoneal cancer- Future Perspectives and Conclusion

Peritoneal cancer Analyst Views

Peritoneal cancer Key Companies


Companies Mentioned

  • Pfizer
  • ImmunoGen
  • Boryung Pharmaceutical
  • OncoQuest
  • Janssen Research & Development
  • OncXerna Theraputics
  • Merck & Co
  • Sotio a.s.
  • AstraZeneca
  • Lee's Pharmaceutical
  • Corcept Therapeutics
  • GlaxoSmithKline
  • Pfizer
  • Bristol-Myers Squibb
  • Seagen Inc.
  • CSPC ZhongQi Pharmaceutical Technology
  • Context Therapeutics
  • Medivation, Inc.
  • Astex Pharmaceuticals
  • APIM Therapeutics
  • Celsion
  • Syndax Pharmaceuticals
  • ImmunoVaccine Technologies
  • Regeneron Pharmaceuticals
  • Mucpharm Pty Ltd
  • Artios Pharma
  • Sumitomo Dainippon Pharma
  • OncoQuest Pharma
  • Genelux Corporation
  • Y-mAbs Therapeutics
  • PGEN Therapeutics
  • Jiangsu HengRui Medicine

For more information about this clinical trials report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900